Last edition
News about "tildrakizumab 100 mg"
Sun Pharmaceutical Industries has reported positive top-line results from two Phase 3 trials (INSPIRE-1 and INSPIRE-2), demonstrating that ILUMYA (tildrakizumab 100 mg) significantly improved symptoms of active psoriatic arthritis over 24 weeks compared to placebo.
Tildrakizumab 100 Mg | 21/07/2025 | By Mrinmoy Dey | 148
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members